<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048069</url>
  </required_header>
  <id_info>
    <org_study_id>037-402-00047</org_study_id>
    <nct_id>NCT05048069</nct_id>
  </id_info>
  <brief_title>Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab.</brief_title>
  <acronym>MCTSRPMS</acronym>
  <official_title>Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab. in Korean Patients With Acute or Chronic Gastritis in Accordance With Korean Regulation, 'Standard for Re-examination of New Drugs'</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This PMS is a non-interventional, prospective, single-arm, multi-center surveillance in&#xD;
      accordance with Korean regulation, 'Standard for Re-Examination of New Drugs'. This PMS is to&#xD;
      assess the safety and effectiveness after administrating Mucosta®SR Tab. Each subject would&#xD;
      be observed for 2 weeks from baseline, if possible. As this PMS is an observational study in&#xD;
      practical medical environment, the subject's follow-up is recommended but not obligatory and&#xD;
      must be left up to the judgment of the investigator.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the &quot;Standards for Re-examination of New Drugs, etc.&quot; of South Korea, this PMS&#xD;
      is conducted in order to collect safety and efficacy information for patients prescribed with&#xD;
      Mucosta®SR Tab. under actual conditions of treatment during the re-examination period of&#xD;
      Mucosta®SR Tab. 150mg (Rebamipide)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall clinical improvement</measure>
    <time_frame>at 2 weeks of treatment</time_frame>
    <description>Improved, No change, Worse The effective rate is defined as the percentage of subjects classified as 'Improved'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the incidence rate and the number of cases for adverse events (AEs)</measure>
    <time_frame>Safety information that occurred from the first administration to 3 days after discontinuation will be collected.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic improvement rate</measure>
    <time_frame>at baseline and 2 weeks</time_frame>
    <description>If upper GI endoscopy is performed at baseline and follow-up visits, the erosion score will be assessed and endoscopic improvement rate at 2 weeks will be evaluated. Endoscopic improvement rate is defined as ≥50% reduction of the erosion score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric symptoms</measure>
    <time_frame>at baseline and 2 weeks</time_frame>
    <description>Presence and type of gastric symptoms at baseline and 2 weeks will be collected.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Acute Gastritis</condition>
  <condition>Chronic Gastritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucosta®SR Tablets 150mg(Rebamipide)</intervention_name>
    <description>adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of&#xD;
        acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab.&#xD;
        according to the medical considerations of the investigator.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) in&#xD;
             acute gastritis or acute exacerbation of chronic gastritis.&#xD;
&#xD;
          2. Patients prescribed with Mucosta®SR Tab. according to the medical considerations of&#xD;
             the investigator.&#xD;
&#xD;
          3. Patients who have given a written informed consent to participation of this PMS and&#xD;
             use of personal information after execution of the contract with the surveillance&#xD;
             study site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with prior history of prescription with Mucosta®SR Tab.&#xD;
&#xD;
          2. Patients with hypersensitivity to Rebamipide or its component ingredients.&#xD;
&#xD;
          3. Patients deemed not suitable for surveillance enrollment according to investigator's&#xD;
             medical judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jooyeup Lee</last_name>
    <phone>010-6435-6172</phone>
    <email>znreina@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Seoul</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yumi An</last_name>
      <phone>02-709-9222</phone>
      <email>s3701@schmc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seongran Jeon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

